Tag: NIH
-
NIH Begins Covid-19 Antibody Trials
National Institutes of Health is beginning clinical trials of experimental antibody therapies to treat Covid-19 infections in people with symptoms ranging from mild to severe.
-
Trial Set for Covid-19 Antibodies in Long-Term Care
Two companies and NIH are beginning a clinical trial of synthetic antibodies to both treat and prevent Covid-19 infections among people in long-term care.
-
NIH Issues Contracts for Faster Covid-19 Diagnostics
National Institutes of Health awarded contracts to seven companies for higher-speed Covid-19 detection tests to ease current reporting delays.
-
NIH Expands Covid-19 Test Technology Challenge
National Institutes of Health is expanding its challenge competition to make tests for Covid-19 viruses more widely available and return results faster.
-
NIH Opens Covid-19 Clinical Trial Network
National Institutes of Health is organizing a collection of sites for late-stage clinical trials to test Covid-19 vaccines and antibody treatments.
-
Dual Antibodies in Trial to Prevent Covid-19 Infections
A cocktail of two synthetic antibodies will soon be tested in a clinical trial to prevent against Covid-19 infections, while also in a trial as a treatment for the disease.
-
Engineered Immune, Stem Cells Studied for HIV Cure
Academic and industry researchers are investigating engineered immune-system cells combined with stem cells as an immunotherapy to neutralize HIV viruses and cure infections.
-
Covid-19 Antibody Therapy Trial Underway
A clinical trial of neutralizing antibodies to treat Covid-19 infections began testing the therapy with hospitalized patients in New York and Los Angeles.
-
NIH Funds Light-Aided Gene Therapy for Eye Disease
A company creating a gene therapy for age-related macular degeneration activated with near-infrared rays received an NIH grant to advance its technology.
-
Covid-19 Vaccine Generates Immune Response
First results from a clinical trial testing a vaccine to protect against Covid-19 infections show the vaccine produces an immune response in healthy participants.